Results 231 to 240 of about 31,287 (242)

Treatment of a patient with end‐stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis

American Journal of Hematology, 2002
Anand P Jillella, Celalettin Ustun
exaly  

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

Diabetes Care, 2014
Carla J Greenbaum, Brian Bundy, Robin Goland   +2 more
exaly  

Rituximab

Reactions Weekly, 2008
openaire   +1 more source

Rituximab

Reactions Weekly, 2023
openaire   +1 more source

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Annals of Oncology, 2011
Andrew M Evens, Yu-Chieh Su, D W Raisch
exaly  

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody‐mediated disease

British Journal of Clinical Pharmacology, 2013
Florent Puisset, Melanie White-Koning, Nassim Kamar   +2 more
exaly  

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen

British Journal of Haematology, 2011
Steven P Tréon, Robert J Manning, Leukothea Ioakimidis   +2 more
exaly  

Rituximab therapy in malignant lymphoma

Oncogene, 2007
B Coiffier, Coiffier B
exaly  

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

Blood, 2009
Tim Illidge, Mike Bayne, Mark S Cragg
exaly  

Rituximab

Reactions Weekly, 2006
openaire   +1 more source